Top Markets
Coin of the day
TaiRx, Inc. TaiRx, Inc.

TaiRx, Inc.

6580
Classifica tra le azioni #25842
TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a... TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for cancer and other diseases. The company's clinical pipeline includes CVM-1118, an oral anti-cancer drug currently undergoing Phase II clinical trials, and Rexis, an add-on injection therapy for sepsis patients, which is in Phase III trials. In its pre-clinical stage, TaiRx is developing TRX-711 for secondary hyperparathyroidism, TRX-920 as an oral delivery formulation, and TRX-105, a molecule designed to treat and alleviate symptoms of various types of colitis. Beyond its developmental drugs, TaiRx also offers Zelnite, a medication that helps maintain patients' blood selenium levels and supports their immune systems. The company's future endeavors also involve the development of nodal diagnostic devices and innovative antibody-based drugs.
Prezzo delle azioni
$0.40861751
Capitalizzazione di mercato
$45.81M
Variazione (1 giorno)
-1.15%
Variazione (1 anno)
-46.41%
Paese
TW
Scambia TaiRx, Inc. (6580)

Categoria

Storico del prezzo dell'azione per TaiRx, Inc. (6580)
Prezzo di chiusura più alto: $0.42 il 2026-08-01

Prezzo di chiusura più basso: $1.41 il 2017-06-01
Storico del prezzo dell'azione di TaiRx, Inc. dal 2017 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) -13.06%
2025 -14.32%
2024 -0.12%
2023 -32.09%
2022 -18.00%
2021 52.04%
2020 57.15%
2019 -14.81%
2018 -18.47%
2017 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$539.14 36.71%
US
$1.04K 56.86%
NL
$120.74 -14.98%
AU
$761.87 7.04%
CH
$130.43 385.07%
US